Skip to content
Screener

Arrowhead Research ARWR Debt Repayments

Debt Repayments at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$0-100%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0-100%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$4.29M-7.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$60.09M

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermLinesOfCredit.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemSix Months Ended March 31, 2026Six Months Ended March 31, 2025
Payments of issuance costs of common stock related to ATM offering(1,324)
Proceeds from issuance of common stock related to follow-on offering130,000
Payments of issuance costs of common stock related to follow-on offering(13,393)
Repayments of credit facility(84,506)(151,625)
Dividends paid by variable interest entity to noncontrolling shareholders(41,514)
Net cash provided by financing activities780,967113,016
Net (decrease) increase in cash, cash equivalents and restricted cash(39,134)83,494
Effect of exchange rate on cash, cash equivalents and restricted cash1,103(470)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's debt repayments?
Arrowhead Research (ARWR) reported debt repayments of $17.83M in Q1 2026.
How has Arrowhead Research's debt repayments changed year-over-year?
Arrowhead Research's debt repayments decreased by 88.2% year-over-year, from $151.63M to $17.83M.
What does debt repayments mean?
Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.

Ask your AI about Arrowhead Research's debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude